drugset / Trial / NCT00646594

Atlantis Symbicort

NCT00646594

Phase 3 Completed 1200 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Symbicort compared with Advair, will be more effective in controlling asthma in adults and adolescents.

Timeline

Start
2003-11
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 320 ug Inhaled
Subject Budesonide Small molecule 640 ug Inhaled
Comparator Fluticasone propionate Other / unclassified 250 ug Inhaled
Subject Formoterol Other / unclassified 9 ug Inhaled
Subject Formoterol Other / unclassified 18 ug Inhaled
Comparator Salmeterol Other / unclassified 50 ug Inhaled

Indications